University of Kansas Medical Center
Below are brief summaries of the 3 enrolling studies. For more information please contact Samantha Colgan at (913-)945-9938 or firstname.lastname@example.org.
The MGA maintains communication with representatives from clinical research studies in efforts to keep the public informed about potential trials MG patients can participate in. Take a look at some of the latest studies below or visit the clinical trials database to discover all the research studies conducted around the world.
Saint Louis University
Dr. Jafar Kafaie - ECU-MG-303 (Pediatric Patients) - Coordinator: Jennifer Light
This clinical trial is specifically for pediatric seropositive gMG patients (ECU-MG-303). This is an open-labeled, multicenter study to evaluate the efficacy, safety, pharmacokinetics, and pharmacodynamics of ECULIZUMAB in PEDIATRIC PATIENTS with generalized Myasthenia Gravis. Dr. Jafar Kafaie of SLU is the PI. Please contact Jennifer Light at email@example.com if interested.
MGChampion Study/Alexion 306
This study is looking at an experimental drug called Ravulizumab, which is given through an IV infusion. This is a randomized control trial in which patients receive either the investigational drug or placebo every 8 weeks for 26 weeks. Once treatment starts the visits are about every 8 weeks and there are some remote options they’ve made available to patients once on treatment. After the first 26 weeks are complete participants will then roll over into an open-label extension where all the patients will be able to receive Ravulizumab. Contact June Smith directly at firstname.lastname@example.org if interested.
Study Website- https://mgchampion.com/
This study is looking at an experimental drug called Rozanolixizumab, which is given through a subcutaneous infusion. This is also a randomized control trial in which the patients receive either the investigational drug or placebo. The infusions are given weekly. This study is 18 weeks with 6 infusions than an observation period. Once completed the participants are given the option to enroll in a separate open-label extension study which would include infusions with the investigational drug. Contact June Smith directly at email@example.com if interested.
Study Website- https://www.mycaringstudy.com/
Dr. Dimachkie – UCB Biopharma MG0003- Coordinator: Ali Ciersdorff
Dr. Dimachkie – Alexion- Coordinator: Katie Jennens
Dr. Farmakidis – Ra Pharma – Coordinator: Samantha Colgan
Washington University School of Medicine in St. Louis
A PDF version of the clinical trials list can be accessed here.